Title: A Systematic Review of Therapuetic Efficacy and Safety of Pramipexole as Adjunctive Therapy for Parkinson's Disease
Abstract:OBJECTIVE:To evaluate therapeutic efficacy and safety of pramipexole as adjunctive therapy for Parkinson's disease(PD). METHODS:Retrived from PubMed,Cochrane Library,EMbase,CBM,CNKI,VIP and Wanfang da...OBJECTIVE:To evaluate therapeutic efficacy and safety of pramipexole as adjunctive therapy for Parkinson's disease(PD). METHODS:Retrived from PubMed,Cochrane Library,EMbase,CBM,CNKI,VIP and Wanfang database,RCTs about pramipexole as adjuctive therapy in the treatment of PD were collected. Rev Man 5.1 software was applied for data analysis.RESULTS:A total of 14 RCTs were included,involving 1 852 patients. Meta-analysis of all studies showed that parmipexole combined with levodopa and Dopa decarboxylase inhibitor could improve total effective rate [OR=3.45,95% CI(2.46,4.85),P0.01],improve the scores of daily living ability [MD=-1.38,95%CI(-2.05,-0.71),P0.01] and the score of motor function[MD=-5.71,95%CI(-9.25,-2.17),P0.01] as well as reduce daily dose of levodopa [MD=-167.42,95%CI(-207.94,-126.90),P0.01]. There was no statistical significance difference between it and levodopa and Dopa decarboxylase inhibitor alone. The incidence of nausea,vomiting,hypotension postural,dizziness and somnolence had no change after parmipexole therapy,but pramipexole might increase the incidence of dyskinesia [OR=2.21,95%CI(1.66,2.95),P0.01],hallucination [OR=3.22,95%CI(2.04,5.09),P0.01] and insomnia [OR=1.52,95%CI(1.00,2.32),P=0.05]. CONCLUSIONS:Clinical efficacy of promipexole as adjunctive therapy is markedly better than levodopa alone in the treatment of PD,but some adverse events induced by pramipexole is higher than control group. However,the results of this systematic review should be considered carefully for the limitation of included studies. High quality large-scale RCTs are required for further validation.Read More
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: review
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot